Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Intra-Articular Injection Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy & Safety of an Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee

NCT02556710
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
4 mL injection of AMPION™, 4 mL injection of Placebo
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 27, 2026, 6:42 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2a to Evaluate the Safety and Efficacy of Adipose Tissue Allograft (BRC-OA) in Patients With Osteoarthritis of the Knee

NCT06828666
View directory record Official record
Conditions
Osteoarthritis of Knee
Interventions
Cryopreserved Devitalized Adipose Tissue Allograft, Normal Saline (Placebo)
Biological · Other
Lead sponsor
Britecyte
Network
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Baltimore, Maryland • Hagerstown, Maryland • Oxon Hill, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 27, 2026, 6:42 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee

NCT03203330
View directory record Official record
Conditions
Degenerative Osteoarthritis
Interventions
TG-C, Placebo Control
Biological
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
40 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 27, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Early Treatment for Acute ACL Tear

NCT01692756
View directory record Official record
Conditions
Anterior Cruciate Ligament (ACL) Tears
Interventions
Kenalog or placebo, Kenalog then Placebo, Kenalog, Placebo
Drug
Lead sponsor
Cale Jacobs
Other
Eligibility
14 Years to 33 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 27, 2026, 6:42 PM EDT
Completed Not applicable Interventional Results available

A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip

NCT01618708
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Synvisc-One (hylan G-F 20), Placebo
Device
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
35 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
45
States / cities
Burmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Sep 27, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional Results available

IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions

NCT02930122
View directory record Official record
Conditions
Anterior Cruciate Ligament Tear
Interventions
anakinra (150mg), Saline intraarticularly
Drug · Other
Lead sponsor
Cale Jacobs, PhD
Other
Eligibility
14 Years to 40 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 27, 2026, 6:42 PM EDT
Recruiting Not applicable Interventional

Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study

NCT06004882
View directory record Official record
Conditions
Peripheral Nerve Stimulation, Genicular Nerves, Chronic Knee Pain
Interventions
PNS therapy, Triamcinolone, Bupivacaine, Placebo
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 27, 2026, 6:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Autologous Conditioned Plasma (ACP) Intra-articular (IA) Injections for Knee Osteoarthritis (OA)

NCT02713542
View directory record Official record
Conditions
Osteoarthritis
Interventions
ACP, Placebo
Device · Other
Lead sponsor
Arthrex, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Columbia, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 27, 2026, 6:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluation of Intra-articular CX-011 to Treat Moderate to Severe Pain From Knee Osteoarthritis

NCT07308834
View directory record Official record
Conditions
Osteoarthritis of the Knees
Interventions
CX-011
Drug
Lead sponsor
CarthroniX, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 27, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee

NCT03182686
View directory record Official record
Conditions
Osteoarthritis, Knee, Knee Osteoarthritis, Knee Arthritis, Knee Pain Chronic
Interventions
4 mL injection of Ampion, 4 mL Injection of Placebo
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
13
States / cities
Birmingham, Alabama • Encinitas, California • Fullerton, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 27, 2026, 6:42 PM EDT
Completed Phase 1 Interventional

Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee

NCT01133613
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Bone morphogenetic protein 7
Drug
Lead sponsor
Stryker Biotech
Industry
Eligibility
40 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Gainesville, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Sep 27, 2026, 6:42 PM EDT
Recruiting Phase 3 Interventional

PRP in ACLR to Prevent PTOA

NCT05412381
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries, Post-traumatic Osteoarthritis, PRP
Interventions
platelet rich plasma (PRP) injection, placebo saline injection
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
14 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 27, 2026, 6:42 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis

NCT05835895
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteo Arthritis Knee, Knee Osteoarthritis
Interventions
GNSC-001, transient immune-modulation, Placebo
Genetic · Drug
Lead sponsor
Genascence Corporation
Industry
Eligibility
40 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
9
States / cities
Mobile, Alabama • La Mesa, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 27, 2026, 6:42 PM EDT
Terminated Phase 3 Interventional Results available

Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee.

NCT03988023
View directory record Official record
Conditions
Severe Osteoarthritis of the Knee
Interventions
Ampion, Saline
Biological · Drug
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 27, 2026, 6:42 PM EDT
Completed Phase 1 Interventional

Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

NCT02095548
View directory record Official record
Conditions
Moderate to Severe Osteoarthritis
Interventions
SM04690, 0.03mg/2mL, SM04690, 0.07mg/2mL, SM04690, 0.23mg/2mL, Placebo
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Tucson, Arizona • El Cajon, California • Walnut Creek, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 27, 2026, 6:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

NCT03379168
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline
Device · Drug
Lead sponsor
Dustin L. Richter, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 27, 2026, 6:42 PM EDT
Active, not recruiting Phase 4 Interventional

Corticosteroid Meniscectomy Randomized Trial

NCT04641351
View directory record Official record
Conditions
Osteoarthritis, Knee, Meniscus Tear, Meniscus; Degeneration, Synovitis
Interventions
Zilretta Injectable Product or Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 27, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

NCT04864392
View directory record Official record
Conditions
Osteoarthritis
Interventions
LNA043, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 27, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

NCT03122860
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
SM04690, Placebo, Sham
Drug · Other
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
74
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 27, 2026, 6:42 PM EDT
Active, not recruiting Not applicable Interventional

Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy

NCT02582489
View directory record Official record
Conditions
Osteoarthritis Post-meniscectomy
Interventions
Bone Marrow Aspirate Concentrate, Standard Meniscectomy
Biological · Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 27, 2026, 6:42 PM EDT
Completed Phase 4 Interventional Results available

Effect of Steroid Injections in a Knee With Osteoarthritis

NCT01230424
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee
Interventions
Triamcinolone Acetonide, 0.9% Sodium Chloride Injection as Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
45 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 27, 2026, 6:42 PM EDT
Active, not recruiting Not applicable Interventional

Non-Surgical Management of Knee Osteoarthritis in the Military Health System (MHS)

NCT03747393
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
DoD/VA CPG Core Set + PT, DoD/VA CPG Core Set
Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 60 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
San Antonio, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 27, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain

NCT03429049
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
CNTX-4975-05, Placebo
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 27, 2026, 6:42 PM EDT
Active, not recruiting Phase 2 Interventional

53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

NCT06865079
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee
Interventions
TPX-100 200mg, Once weekly for 4 weeks, PBS
Drug · Other
Lead sponsor
OrthoTrophix, Inc
Industry
Eligibility
50 Years to 80 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
33
States / cities
Scottsdale, Arizona • Tucson, Arizona • Carrolton, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 27, 2026, 6:42 PM EDT